Short list of questions for Pfizer executives. (Bailiwick News)

For use by those who hold authority to compel responses from Pfizer, and prohibit use of and seize vials within their political jurisdictions when full and frank disclosures are not forthcoming.

Resource Link for Short list of questions for Pfizer executives. (Bailiwick News) (opens new window)

Below is a subset/reworking of items from a larger set of draft discovery materials.

  • April 28, 2023 – Draft discovery materials for civil and criminal cases. Useful for promoting understanding that the factual record of events since January 2020 supports the legal conclusion that products labeled ‘vaccines’ are presumptive injectable biochemical weapons.

With respect to establishing Pfizer’s legal position on the applicability and enforceability of current Good Manufacturing Practice regulations (cGMP) as promulgated and enforced by FDA (PDF):

1. Produce signed, dated, unredacted copies of the following three (3) contract documents, pertaining to Department of Defense Other Transaction Authority project OTA W15QKN-16-9-1002:

  • July 20, 2020 Medical CBRN Defense Consortium (MCDC) “Base Agreement” No. 2020-532, between Advanced Technology International (ATI) and Pfizer, Inc. [Redacted copy released to public through Jackson v. Ventavia, Pfizer, ICON];
  • July 21, 2020 “Technical Direction Letter” for Medical CRBN Defense Consortium (MCDC) Request for Prototype Proposals (RPP) 20-11, Objective PRE-20-11 for COVID-19 Pandemic – Large Scale Vaccine Manufacturing Demonstration, between Advanced Technology International (ATI) and Pfizer, Inc. [Redacted copy released to public through Jackson v. Ventavia, Pfizer, ICON];
  • ATI-DOD-Pfizer “Project Agreement” 2011-003 under OTA W15QKN-16-9-1002, defined at p. 9 of July 20, 2020 Base Agreement, under which Pfizer is the Project Agreement Holder (“PAH”) [As of Nov. 6, 2023, the “Project Agreement” has not been disclosed to public in any form, to my knowledge.]

2. Identify all US federal drug manufacturing, quality control, labeling, distribution and related regulations, by Code of Federal Regulations (CFR) citation, applicable to Pfizer’s development, manufacturing, quality control, labeling and distribution of the products known as “Covid-19 vaccines.” Regulations that may apply include but are not limited to: 21 CFR 210, 21 CFR 211, 21 CFR 600; 21 CFR 601 and 21 CFR 820.

3. Produce signed, dated, unredacted copies of all documents Pfizer submitted to the FDA to comply with the terms of each applicable regulation between January 2020 and the present.

4. Produce signed, dated, unredacted copies of all documents Pfizer received from the FDA pertaining to compliance review and enforcement of each applicable regulation between January 2020 and the present.

5. List all contract terms and conditions, by contract title, date, section and page number, applicable to, and/or enforceable by parties, pertaining to Pfizer’s manufacturing, quality control, labeling and distribution of the products known as “Covid-19 vaccines.”

6. Produce signed, dated, unredacted copies of all documents Pfizer submitted to contract counterparties (ATI/US Department of Defense) documenting compliance with each applicable, enforceable contract term/condition between January 2020 and the present.

7. Produce signed, dated, unredacted copies of all documents Pfizer submitted to contract counterparties (ATI/US Department of Defense) documenting compliance with each applicable, enforceable CFR regulation governing product manufacturing, quality control, labeling and distribution between January 2020 and the present.


Earlier drafts of these interrogative materials were prepared for and submitted to Senator Ron Johnson in January 2023. As of November 2023, Johnson remains impervious to requests that he act publicly upon the information provided.


Pfizer manufactures the class of biochemical weapons known as “Covid-19 vaccines” knowing that no CFR pharmaceutical cGMP regulations are or ever were applicable to the raw materials entering and finished products leaving Pfizer-labeled facilities; that DoD, FDA, ATI and DOJ would not, did not and do not enforce cGMP compliance; and that therefore no record of compliance or enforcement activity exists.

These questions are drafted to give Pfizer an opportunity to admit those facts to anyone who has the authority to compel responses from Pfizer, and to help those authorities properly interpret Pfizer’s anticipated refusal to provide the requested documentation as confirmation of the state of war that currently exists between infiltrators posing as US Government officials, and their military targets: the people of the United States, civilian and military alike.

Note:

Pfizer is just one of many military contractors producing biochemical weapons for the US Department of Defense and labeling them as ‘vaccines’ and other medicinal products.

This set of questions is addressed to Pfizer as the named respondent only because Pfizer-labeled products have been the focus of recent public discussion of contamination; adulteration; cGxP non-compliance; and FDA non-enforcement of cGxP regulations.

These questions and document demands can be revised and addressed to Moderna, Johnson & Johnson and many other DoD contractors to solicit the same responses and non-responses.


Related reporting and analysis:

Resource Category: COVID



As censorship increases also consider using email and text messages to send links.

Leave a Reply

Your email address will not be published. Required fields are marked *